SCHEMBL23218306

SCHEMBL23218306

COC(=O)c1ccccc1OCc1coc2ccc(-c3cccc(CN)c3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 5/20 0.46
PLG P00747 2/20 0.46
PLAU P00749 2/20 0.46
F11 P03951 2/20 0.46
TPSB2 P20231 2/20 0.46
KLKB1 P03952 1/20 0.46
F7 P08709 1/20 0.46
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
VDR P11473 2/20 0.41
LOXL2 Q9Y4K0 1/20 0.40
TP53 P04637 1/20 0.38
PARP1 P09874 1/20 0.38
AKR1C1 Q04828 1/20 0.38
KDM4E B2RXH2 2/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852729 1.00 CFD (0.46) CFDPLGPLAUF11TPSB2
SCHEMBL23218267 0.89 CFD (0.51) CFDPLGPLAUF11TPSB2
SCHEMBL29592855 0.89 CFD (0.51) CFDPLGPLAUF11TPSB2
SCHEMBL29592336 0.83 CFD (0.70) CFDPLGPLAUF11TPSB2
SCHEMBL23218477 0.83 CFD (0.70) CFDPLGPLAUF11TPSB2
SCHEMBL23218893 0.81 CFD (0.52) CFDPLGPLAUF11TPSB2
SCHEMBL29591816 0.81 CFD (0.52) CFDPLGPLAUF11TPSB2
SCHEMBL23218314 0.81 CFD (0.56) CFDPLGPLAUF11TPSB2
SCHEMBL29593126 0.81 CFD (0.56) CFDPLGPLAUF11TPSB2
SCHEMBL23218760 0.81 CFD (0.54) CFDPLGPLAUF11TPSB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885PLG 421/4885PLAU 1119/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885PLG 89/4885PLAU 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.